Atypical Alzheimer’s Disease: Why Current Treatment Criteria Fall Short
Current clinical trial and treatment eligibility frameworks exclude a vast majority of patients suffering from atypical Alzheimer’s disease, even during the early stages of symptom progression. Regulatory thresholds, biomarker screening … Read More